Orforglipron (Foundayo) Dosage Chart
The 3mg → 36mg once-daily oral schedule, doses & price
Foundayo is the brand name for orforglipron, Eli Lilly’s once-daily oral GLP-1 pill. In its trials it is titrated slowly from 3mg upward to limit nausea, with the highest studied maintenance dose around 36mg. This chart summarizes that schedule, the doses studied, and what is known about price and availability. Orforglipron is investigational and not yet FDA approved, so this is a trial-based reference, not an approved dosing label.
How orforglipron (Foundayo) is dosed
Orforglipron is a once-daily oral tablet. Unlike oral semaglutide (Rybelsus), it is a non-peptide small molecule, so it does not require fasting or strict water-timing — it can be taken with or without food. Like all GLP-1 drugs, it is started low and increased gradually to reduce gastrointestinal side effects.
In the ATTAIN Phase 3 program (and the earlier Phase 2 trial), participants escalated from a 3mg starting dose roughly every 4 weeks toward maintenance doses, with the highest studied around 36mg. Because it is investigational, there is no FDA-approved label dose yet — the schedule below reflects the trial titration.
Orforglipron (Foundayo) titration schedule (3mg → 36mg)
| Dose | Typical timing | Purpose |
|---|---|---|
| 3 mg | Weeks 1–4 | Starter / tolerance dose (not therapeutic)Best |
| 6 mg | Weeks 5–8 | Continued tolerance building |
| 12 mg | Weeks 9–12 | First maintenance option |
| 24 mg | Weeks 13–16 | Step-up if more effect needed |
| 36 mg | Week 17+ | Highest studied maintenance dose |
Price & availability (what we know)
There is no official Foundayo (orforglipron) price yet, because pricing is set at approval and it is still investigational. Expect that to change once it clears FDA review, which is anticipated as its Phase 3 ATTAIN data reports.
On context: as an oral pill, orforglipron is expected to be easier and cheaper to manufacture and distribute than injectable GLP-1s, and Lilly has signaled an interest in broad access — so analysts widely expect competitive pricing versus injectables (which list around $1,000+ per month before insurance and savings programs). International interest is high (UK, India, USA, UAE), but availability and price will roll out by market after approval.
Bottom line: any specific monthly price circulating now is speculation. When it launches, cost will depend on list price, insurance, and manufacturer savings — track what you actually pay in Shotlee.
Safety & titration notes
The main side effects in trials were gastrointestinal (nausea, vomiting, diarrhea, constipation), dose-dependent and reduced by slow titration — the reason the schedule steps up gradually. Holding a dose longer is a common way to manage symptoms.
This page is an educational reference about how orforglipron was dosed in studies. It is not a recommendation to obtain or use an unapproved drug; decisions belong with a qualified healthcare professional once it is available.
Guide FAQs
In trials it started at 3 mg once daily and stepped up about every 4 weeks — 3 → 6 → 12 → 24 → 36 mg — toward a maintenance dose, escalated only as tolerated. It is investigational, so this is a trial schedule, not an approved label.
The highest studied maintenance dose is around 36 mg once daily. Lower maintenance doses (12 or 24 mg) were also used; the final dose depends on response and tolerability.
There is no official price yet — it is set at approval. As an oral pill it is expected to be cheaper to make than injectables and is widely expected to be priced competitively, but any specific figure now is speculation. Cost will depend on list price, insurance, and savings programs.
Yes. Foundayo (orforglipron) is a once-daily oral non-peptide GLP-1 receptor agonist from Eli Lilly. It hits the same GLP-1 receptor as Ozempic/Wegovy, but as a small-molecule pill rather than an injection.
No. Orforglipron is investigational and not yet FDA approved. Availability will follow approval, anticipated as its Phase 3 ATTAIN data reports. Follow Shotlee’s tracker pages for updates.
Unlike oral semaglutide (Rybelsus), orforglipron is a non-peptide pill that does not require fasting or strict water-timing — it can be taken with or without food, a key convenience advantage.
Yes. Shotlee logs each daily dose, reminds you when to escalate, and tracks side effects, weight, and what you pay — free.
Track Foundayo (Orforglipron) in Shotlee
Log each daily dose, get escalation reminders, and track side effects, weight, and cost — free.